Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of BDB-001 in ANCA-associated vasculitis
CTR20253611Phase 3Active
- Sponsor
- 舒泰神（北京）生物制药股份有限公司；北京德丰瑞生物技术有限公司/ 舒泰神（北京）生物制药股份有限公司
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BDB-001 in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), sponsored by 舒泰神（北京）生物制药股份有限公司；北京德丰瑞生物技术有限公司/ 舒泰神（北京）生物制药股份有限公司. Started Nov 2025; status: active.
02
Drugs
BDB-001
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on CTR20253611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253611.